Why the study?
What are the clinical and pathologic features of amiodarone-associated pulmonary toxicity in patients receiving the drug?
Population
171 patients receiving amiodarone, of which 11 developed amiodarone-associated pulmonary toxicity (APT)
Design
Case_series
Authors
Loading...
Amiodarone recipients warrant close pulmonary monitoring; this case report leaves open optimal discontinuation strategies to avert fatal arrhythmias.
What are the clinical and pathologic features of amiodarone-associated pulmonary toxicity in patients receiving the drug?
Amiodarone causes a reversible pulmonary toxicity characterized by diffuse alveolar damage and drug-induced phospholipidosis, occurring in approximately 6.4% of treated patients.
Dean et al. (1987) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: